Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | FABP1 | P07148 | 3/20 | 0.33 |
| ▸ | CCR1 | P32246 | 4/20 | 0.33 |
| ▸ | CCR8 | P51685 | 4/20 | 0.33 |
| ▸ | CCR5 | P51681 | 3/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629705 | 0.82 | MAPT (0.34) | MAPTKDM4ENPSR1FABP1CCR1 | |
| SCHEMBL16629614 | 0.82 | CCR1 (0.36) | MAPTKDM4ENPSR1BRD4FABP1 | |
| SCHEMBL13371453 | 0.82 | AKT1 (0.37) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL16629676 | 0.82 | NPY5R (0.32) | MAPTKDM4ENPSR1BRD4AVPR2 | |
| SCHEMBL17946226 | 0.82 | CCR1 (0.40) | MAPTKDM4ENPSR1BRD4FABP1 | |
| SCHEMBL13371011 | 0.82 | MEN1 (0.40) | MAPTKDM4EAVPR2AVPR1AMEN1 | |
| SCHEMBL13353708 | 0.81 | ERBB2 (0.34) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL16629903 | 0.81 | CYP3A4 (0.33) | MAPTKDM4ENPSR1BRD4FABP1 | |
| SCHEMBL16629632 | 0.81 | METAP2 (0.33) | MAPTMETAP2HTTALDH1A1 | |
| SCHEMBL13371400 | 0.80 | MEN1 (0.36) | MAPTKDM4EMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | MERCK PATENT GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| WO-2015049022-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | KCNQ1, KCNH1, KCNQ2 | MAPT 2400/4885KDM4E 1939/4885NPSR1 1205/4885 |
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | KCNQ1, KCNH1, KCNQ2 | MAPT 2400/4885KDM4E 1939/4885NPSR1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.